These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 19594748)

  • 1. NKG2D-mediated immunity underlying paroxysmal nocturnal haemoglobinuria and related bone marrow failure syndromes.
    Hanaoka N; Nakakuma H; Horikawa K; Nagakura S; Tsuzuki Y; Shimanuki M; Kojima K; Yonemura Y; Kawaguchi T
    Br J Haematol; 2009 Sep; 146(5):538-45. PubMed ID: 19594748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoselection by natural killer cells of PIGA mutant cells missing stress-inducible ULBP.
    Hanaoka N; Kawaguchi T; Horikawa K; Nagakura S; Mitsuya H; Nakakuma H
    Blood; 2006 Feb; 107(3):1184-91. PubMed ID: 16195329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble NKG2D Ligands Are Potential Biomarkers and Sentinels of Immune-Mediated Bone Marrow Injury in Bone Marrow Failure Syndromes.
    Murata S; Mushino T; Hosoi H; Kuriyama K; Nishikawa A; Nagakura S; Horikawa K; Yonemura Y; Nakakuma H; Sonoki T; Hanaoka N
    Acta Haematol; 2020; 143(1):33-39. PubMed ID: 31216534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of abnormal clones by the fluorescent aerolysin method in paroxysmal nocturnal haemoglobinuria and other marrow disorders.
    Agarwal R; Chapple P; Brown M; Szer J; Juneja S
    Int J Lab Hematol; 2015 Feb; 37(1):14-21. PubMed ID: 24702736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cells expressing the activating NK-cell receptors KIR2DS4, NKG2C and NKG2D are elevated in paroxysmal nocturnal hemoglobinuria and cytotoxic toward hematopoietic progenitor cell lines.
    van Bijnen ST; Withaar M; Preijers F; van der Meer A; de Witte T; Muus P; Dolstra H
    Exp Hematol; 2011 Jul; 39(7):751-62.e1-3. PubMed ID: 21554925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome.
    Maciejewski JP; Follmann D; Nakamura R; Saunthararajah Y; Rivera CE; Simonis T; Brown KE; Barrett JA; Young NS
    Blood; 2001 Dec; 98(13):3513-9. PubMed ID: 11739151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular pathogenesis of bone marrow failure in paroxysmal nocturnal hemoglobinuria: a role of NKG2D-medicated immunity].
    Kawaguchi T
    Rinsho Ketsueki; 2010 Aug; 51(8):664-71. PubMed ID: 20805673
    [No Abstract]   [Full Text] [Related]  

  • 8. Killer immunoglobulin-like receptor genotype in immune-mediated bone marrow failure syndromes.
    Howe EC; Wlodarski M; Ball EJ; Rybicki L; Maciejewski JP
    Exp Hematol; 2005 Nov; 33(11):1357-62. PubMed ID: 16263420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apoptosis resistance of blood cells from patients with paroxysmal nocturnal hemoglobinuria, aplastic anemia, and myelodysplastic syndrome.
    Horikawa K; Nakakuma H; Kawaguchi T; Iwamoto N; Nagakura S; Kagimoto T; Takatsuki K
    Blood; 1997 Oct; 90(7):2716-22. PubMed ID: 9326238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between bone marrow failure syndromes and the presence of glycophosphatidyl inositol-anchored protein-deficient clones.
    Maciejewski JP; Rivera C; Kook H; Dunn D; Young NS
    Br J Haematol; 2001 Dec; 115(4):1015-22. PubMed ID: 11843844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria.
    Mannelli F; Bencini S; Peruzzi B; Cutini I; Sanna A; Benelli M; Magi A; Gianfaldoni G; Rotunno G; Carrai V; Gelli AM; Valle V; Santini V; Notaro R; Luzzatto L; Bosi A
    Cytometry B Clin Cytom; 2013 Mar; 84(2):71-81. PubMed ID: 23281097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
    Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
    Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quercetin enhances susceptibility to NK cell-mediated lysis of tumor cells through induction of NKG2D ligands and suppression of HSP70.
    Bae JH; Kim JY; Kim MJ; Chang SH; Park YS; Son CH; Park SJ; Chung JS; Lee EY; Kim SH; Kang CD
    J Immunother; 2010 May; 33(4):391-401. PubMed ID: 20386467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulated expression of NKG2D and its ligands give potential therapeutic targets for patients with thymoma.
    Xuan XY; Zhang JF; Hu GM; Li QR; Liu PP; Du Y
    Cancer Gene Ther; 2015 Jul; 22(7):368-74. PubMed ID: 26113176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insights into molecular pathogenesis of bone marrow failure in paroxysmal nocturnal hemoglobinuria.
    Kawaguchi T; Nakakuma H
    Int J Hematol; 2007 Jul; 86(1):27-32. PubMed ID: 17675263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of paroxysmal nocturnal haemoglobinuria clone presence in aplastic anaemia patients treated with combined immunosuppression: results of two-centre prospective study.
    Kulagin A; Lisukov I; Ivanova M; Golubovskaya I; Kruchkova I; Bondarenko S; Vavilov V; Stancheva N; Babenko E; Sipol A; Pronkina N; Kozlov V; Afanasyev B
    Br J Haematol; 2014 Feb; 164(4):546-54. PubMed ID: 24261566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Origin and fate of blood cells deficient in glycosylphosphatidylinositol-anchored protein among patients with bone marrow failure.
    Sugimori C; Mochizuki K; Qi Z; Sugimori N; Ishiyama K; Kondo Y; Yamazaki H; Takami A; Okumura H; Nakao S
    Br J Haematol; 2009 Oct; 147(1):102-12. PubMed ID: 19656154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
    Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
    Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
    Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
    FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential Expression of CD52, CD14 and HLA-DR on CD4+ Monocytes in Three Types of Acquired Bone Marrow Failure Syndromes.
    Kai Y; Yuanyuan D; Shihe G; Xuanxuan M; Hao Z; Ying P; Yuanyuan W; Aihua W; Beibei S; TongYang ; Tingdong Z
    Clin Lab; 2016 Sep; 62(9):1767-1772. PubMed ID: 28164595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.